OpGen, Inc. (NASDAQ:OPGN)’s share price fell 6.3% during trading on Wednesday . The stock traded as low as $0.30 and last traded at $0.30. 1,025,782 shares changed hands during trading, a decline of 41% from the average session volume of 1,752,050 shares. The stock had previously closed at $0.32.

Several research firms recently commented on OPGN. Dawson James restated a “buy” rating on shares of OpGen in a research report on Monday, June 19th. HC Wainwright restated a “buy” rating and set a $1.00 target price on shares of OpGen in a research report on Monday. Finally, Zacks Investment Research upgraded OpGen from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a research report on Tuesday, August 15th.

The stock has a 50-day moving average price of $0.32 and a 200-day moving average price of $0.83. The stock’s market capitalization is $15.47 million.

In other news, CFO Timothy C. Dec acquired 65,000 shares of the business’s stock in a transaction dated Tuesday, July 18th. The stock was purchased at an average price of $0.40 per share, for a total transaction of $26,000.00. Following the completion of the transaction, the chief financial officer now directly owns 118,966 shares in the company, valued at approximately $47,586.40. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Jven Capital, Llc acquired 1,875,000 shares of the business’s stock in a transaction dated Tuesday, July 18th. The shares were purchased at an average price of $0.40 per share, with a total value of $750,000.00. The disclosure for this purchase can be found here. Company insiders own 53.27% of the company’s stock.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. grew its position in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned approximately 1.25% of OpGen worth $219,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 8.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “OpGen, Inc. (OPGN) Stock Price Down 6.3%” was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/opgen-inc-opgn-stock-price-down-6-3/1560034.html.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.